Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Iovance Biotherapeutics, Inc. - Common Stock
(NQ:
IOVA
)
3.060
-0.010 (-0.33%)
Official Closing Price
Updated: 4:15 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Iovance Biotherapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Why Iovance Biotherapeutics Stock Soared 12% Higher Today
January 23, 2023
A business, clinical, and regulatory update lifted the spirits of investors.
Via
The Motley Fool
Iovance Biotherapeutics Acquires Clinigen's IL-2 Product For Upfront £166.7M
January 23, 2023
Via
Benzinga
Iovance Biotherapeutics Provides Corporate, Clinical, and Regulatory Updates
January 23, 2023
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
What 6 Analyst Ratings Have To Say About Iovance Biotherapeutics
December 09, 2022
Via
Benzinga
Why Is Iovance Biotherapeutics (IOVA) Stock Soaring 20% Today?
December 05, 2022
Although Iovance Biotherapeutics cuts a speculative figure, IOVA stock managed to skyrocket on Monday off insider buying.
Via
InvestorPlace
Why Iovance Biotherapeutics Shares Are Trading Higher By Around 19%? Here Are 40 Stocks Moving In Monday's Mid-Day Session
December 05, 2022
Gainers Winc, Inc. (NYSE: WBEV) rose 88.5% to $0.3901 after dropping over 23% on Friday. Winc, last month, posted a Q3 loss of $0.33 per share.
Via
Benzinga
What 4 Analyst Ratings Have To Say About Iovance Biotherapeutics
November 21, 2022
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
December 05, 2022
Via
Benzinga
US Stocks Start Week On Lower Note; Dow Tumbles 250 Points
December 05, 2022
U.S. stocks traded lower this morning, with the Dow Jones falling around 250 points on Monday.
Via
Benzinga
Iovance Biotherapeutics Stock Is Surging: Here's Why
December 05, 2022
Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares are trading higher Monday following recent insider buying from Director Wayne Rothbaum.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
December 05, 2022
Via
Benzinga
$65 Million Bet On Iovance Biotherapeutics? Check Out These 3 Stocks Insiders Are Buying
December 05, 2022
Although US stocks closed mixed on Friday, there were a few notable insider trades.
Via
Benzinga
Recap: Iovance Biotherapeutics Q3 Earnings
November 03, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) reported its Q3 earnings results on Thursday, November 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Iovance Biotherapeutics to Present at Upcoming Conferences
November 30, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
NIO To Surge Around 105%? Plus Keybanc Predicts $165 For This Stock
November 21, 2022
Keybanc raised the price target on AMETEK, Inc. (NYSE: AME) from $145 to $165. Keybanc analyst Steve Barger maintained an Overweight rating on the stock. AMETEK shares rose 0.9% to close at $139.32 on...
Via
Benzinga
Why Iovance Biotherapeutics Is Crashing Today
November 18, 2022
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Via
The Motley Fool
Iovance Biotherapeutics Pushes FDA Rolling Submission Deadline Into Next Year For Its Lead Skin Cancer Candidate
November 18, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 18, 2022
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
November 18, 2022
It's time to start closing out the trading week with a dive into the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
Iovance Biotherapeutics Provides Update on Biologics License Application Submission for Lifileucel in Advanced Melanoma
November 18, 2022
BLA Submission Ongoing with U.S. Food and Drug Administration
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
November 15, 2022
Gainers Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) shares surged 113.8% to settle at $20.10 on Monday. Indivior PLC agreed to acquire Opiant Pharmaceuticals for $20.00 per share in cash, plus...
Via
Benzinga
Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 07, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates
November 03, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Preview: Iovance Biotherapeutics's Earnings
November 02, 2022
Iovance Biotherapeutics (NASDAQ:IOVA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 3, 2022
October 24, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
Iovance Biotherapeutics Announces First Patient Dosed with PD-1 Inactivated Tumor Infiltrating Lymphocyte (TIL) Therapy
October 10, 2022
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
Iovance Biotherapeutics to Present Clinical Data for Lifileucel Tumor Infiltrating Lymphocyte (TIL) Therapy in Advanced Melanoma at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
October 05, 2022
Oral Presentation of C-144-01 Trial Cohorts 2 and 4
From
Iovance Biotherapeutics, Inc.
Via
GlobeNewswire
5 Top Stocks Cathie Wood Is Selling This Week
August 26, 2022
Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.
Via
InvestorPlace
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.